Additionally, the treatment with madecassoside also downregulated the translocation and phosphorylation of NF-κB, suggesting an anti-RA activity related to the inhibition of the NF-κB/MMP-13 pathway [108]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.